Virtual Library
Start Your Search
C. Kristiansen
Author of
-
+
P1.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 209)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Localized Disease - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P1.02-039 - Stereotactic Radiotherapy as Salvage Treatment after Stereotactic Radiotherapy or after Operated Non-Small-Cell Lung Cancer (ID 2240)
09:30 - 17:00 | Author(s): C. Kristiansen
- Abstract
Background:
Lobectomy is regarded as the standard of care for early stage non-small-cell lung cancer (NSCLC), but stereotactic radiotherapy (SBRT) is an option for patients who are not candidates for surgery. Although the curative intention treatments, a significant proportion of patients with NSCLC will develop recurrent disease. For patients previously treated with SBRT little is known of retreatment with SBRT in the recurrent setting.
Methods:
All patients with lung cancer treated at our center with SBRT have been registered prospectively. We identified the patients who had salvage SBRT after prior pulmonary surgery or SBRT. Overall survival was calculated from the day of salvage SBRT.
Results:
Between November 2008 and February 2015, 198 patients were treated with SBRT. We identified 24 patients that had received SBRT as salvage treatment for their first recurrence in the lung. Surgery was the initial treatment for 13 of the patients (OP-group) and SBRT was the initial treatment for the remaining 11 patients (RT-group). By the end of follow up, 5 patients in the OP-group had died and 3 in the RT-group. In the OP-group all the salvage SBRT was given as 66 Gy in 3 fractions. In the SB-group, 5 was treated with 56 Gy in 8 fractions, 1 with 45 Gy in 3 fraction and 1 with 45 Gy in 10 fractions when given salvage SBRT.Primary surgery Primary SBRT All Number of patients 13 11 24 Age mean (range) 75 (62-88) 69 (53-87) 72 (53-88) Histology Plano/Adeno/NOS 3/8/2 4/5/2 7/13/4 Time in months from primary treatment to salvage SBRT median (range) 65 (4-236) 17 (5-44) 21 (4-236) Survival time from SBRT 1 year (%) 2 year (%) 85 62 89 61 87 60 Median follow-up months (range) 27.6 (14.3-62.8) 15.9 (1.4-32.9) 21 (1.4-62.9) Lung function FEV1, median (range 1.4 (0.6-2.7) 1.4 (0.4-2.8) 1.4 (0.4-2.8) ECOG Performance Status 0 1 2 3 4 5 3 1 1 2 7 1 5 7 10 2
Conclusion:
Although the time from primary treatment to salvage SBRT was longer if surgery was the primary treatment than if the primary treatment was SBRT, the overall survival was equal for the two groups.
